Javascript must be enabled to continue!
Abstract 3492: The small GTPase ARF6 augments BRAFV600E-MAPK signaling in melanomagenesis
View through CrossRef
Abstract
ARF6 is a member of the Ras superfamily of small GTPases and has critical functions in endo-membrane trafficking pathways. We previously reported that ARF6 is aberrantly activated in metastatic melanoma and that activation of ARF6 stimulates WNT5A/beta-catenin and PI3K/AKT signaling to promote invasion and accelerate metastasis. Herein, we discovered an ARF6 activation signature in primary melanomas that is associated with inferior overall survival, supporting a novel role for ARF6 in early-stage progression. Conversely, melanocyte-specific deletion of Arf6 in Dct;TVA::BrafV600E;Cdkn2aNull murine melanoma significantly reduced tumorigenesis and progression, and improved survival. Importantly, bulk tumor transcriptome analysis showed reduced expression of ERK-induced genes in these BRAFV600E tumors. Likewise, immunofluorescent staining of tumor sections showed a significant reduction of cytoplasmic and nuclear p-ERK levels. Together these data demonstrate that loss of ARF6 reduces BRAFV600E-MAPK signaling output in vivo. This is a provocative finding because it implies that endomembrane trafficking has a major role in promoting BRAFV600E-driven tumorigenesis. More specifically, ARF6 may be critical for augmenting BRAFV600E signaling. Consistent with this hypothesis, expression of activated ARF6(ARF6Q67L) in our murine BRAFV600E melanoma cells was associated with upregulation of BRAFV600E, p-MEK, and p-ERK levels, detected by Reverse Phase Protein Array analysis. In addition, ARF6Q67L tumor cells showed an increase in anti-apoptotic proteins with a reciprocal decrease in pro-apoptotic proteins. Knockdown of Arf6 in BRAFV600E human melanoma cells significantly reduced proliferation and sensitized cells to vemurafenib-induced apoptosis. Overall, our data reveal that ARF6 augments MAPK signaling in BRAFV600E-driven tumorigenesis. Further work is needed to understand if ARF6 mediates endomembrane-dependent signaling of the BRAFV600E-MAPK pathway.
Citation Format: Junhua Wang, Aaron Rogers, Coulson Rich, Lise Sorensen, Sheri Holmen, Roger Wolff, Allie Grossmann. The small GTPase ARF6 augments BRAFV600E-MAPK signaling in melanomagenesis [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3492.
American Association for Cancer Research (AACR)
Title: Abstract 3492: The small GTPase ARF6 augments BRAFV600E-MAPK signaling in melanomagenesis
Description:
Abstract
ARF6 is a member of the Ras superfamily of small GTPases and has critical functions in endo-membrane trafficking pathways.
We previously reported that ARF6 is aberrantly activated in metastatic melanoma and that activation of ARF6 stimulates WNT5A/beta-catenin and PI3K/AKT signaling to promote invasion and accelerate metastasis.
Herein, we discovered an ARF6 activation signature in primary melanomas that is associated with inferior overall survival, supporting a novel role for ARF6 in early-stage progression.
Conversely, melanocyte-specific deletion of Arf6 in Dct;TVA::BrafV600E;Cdkn2aNull murine melanoma significantly reduced tumorigenesis and progression, and improved survival.
Importantly, bulk tumor transcriptome analysis showed reduced expression of ERK-induced genes in these BRAFV600E tumors.
Likewise, immunofluorescent staining of tumor sections showed a significant reduction of cytoplasmic and nuclear p-ERK levels.
Together these data demonstrate that loss of ARF6 reduces BRAFV600E-MAPK signaling output in vivo.
This is a provocative finding because it implies that endomembrane trafficking has a major role in promoting BRAFV600E-driven tumorigenesis.
More specifically, ARF6 may be critical for augmenting BRAFV600E signaling.
Consistent with this hypothesis, expression of activated ARF6(ARF6Q67L) in our murine BRAFV600E melanoma cells was associated with upregulation of BRAFV600E, p-MEK, and p-ERK levels, detected by Reverse Phase Protein Array analysis.
In addition, ARF6Q67L tumor cells showed an increase in anti-apoptotic proteins with a reciprocal decrease in pro-apoptotic proteins.
Knockdown of Arf6 in BRAFV600E human melanoma cells significantly reduced proliferation and sensitized cells to vemurafenib-induced apoptosis.
Overall, our data reveal that ARF6 augments MAPK signaling in BRAFV600E-driven tumorigenesis.
Further work is needed to understand if ARF6 mediates endomembrane-dependent signaling of the BRAFV600E-MAPK pathway.
Citation Format: Junhua Wang, Aaron Rogers, Coulson Rich, Lise Sorensen, Sheri Holmen, Roger Wolff, Allie Grossmann.
The small GTPase ARF6 augments BRAFV600E-MAPK signaling in melanomagenesis [abstract].
In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL.
Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 3492.
Related Results
Abstract 1997: The small GTPase ARF6 augments BRAF and PI3K expression to promote melanoma survival
Abstract 1997: The small GTPase ARF6 augments BRAF and PI3K expression to promote melanoma survival
Abstract
RAF and MEK inhibitors greatly benefit BRAF-mutant melanoma patients, but eventually, nearly 80% of patients relapse. Reactivation of MAPK signaling and act...
Abstract A05: ARF6 inhibition enhances T cell-mediated cytotoxicity in triple negative breast cancer
Abstract A05: ARF6 inhibition enhances T cell-mediated cytotoxicity in triple negative breast cancer
Abstract
Triple negative breast cancer (TNBC) has the poorest clinical outcome owing to the lack of effective treatments out of all the breast cancer subtypes. Immun...
Clinical Implications of Cell-Free DNA in Managing BRAF V600E Mutation-Positive Colorectal Cancer
Clinical Implications of Cell-Free DNA in Managing BRAF V600E Mutation-Positive Colorectal Cancer
Background/Objectives:Â BRAFV600E-mutant colorectal cancer (CRC) is associated with poor prognosis, and despite the introduction of BEACON therapy, significant treatment challenges ...
Abstract 6979: Uncovering the BRAF interactome to identify novel therapeutic targets for BRAF driven melanoma and lung cancer
Abstract 6979: Uncovering the BRAF interactome to identify novel therapeutic targets for BRAF driven melanoma and lung cancer
Abstract
BRAF protein kinases act downstream of RAS-GTP and upstream of MEK>ERK MAP Kinase signaling. Notably, mutational activation of BRAF is a driver of ap...
The small GTPase Arf6 functions as a membrane tether in a chemically-defined reconstitution system
The small GTPase Arf6 functions as a membrane tether in a chemically-defined reconstitution system
Abstract
Arf-family small GTPases are essential protein components for membrane trafficking in all eukaryotic endomembrane systems, particularly ...
Abstract 920: COP1 E3 ligase regulates response to oncogenic MAPK pathway inhibition
Abstract 920: COP1 E3 ligase regulates response to oncogenic MAPK pathway inhibition
Abstract
Oncogenically activated RAS-MAPK pathway is the driver of several cancers including the majority of non-small cell lung adenocarcinomas (NSCLC). RAS-MAPK pa...
Abstract 1864: Baicalein attenuates endometrial cancer growth by suppressing the ARF6
Abstract 1864: Baicalein attenuates endometrial cancer growth by suppressing the ARF6
Abstract
Using mass spectrometry-based proteomics, we have previously shown enhanced expression of the Adenosine diphosphate-Ribosylation Factor-6 (ARF6) in endometr...
Application of Ultrasound Shear Wave Elastography Combined With BRAFV600E Mutation for the Diagnosis of Papillary Thyroid Carcinoma
Application of Ultrasound Shear Wave Elastography Combined With BRAFV600E Mutation for the Diagnosis of Papillary Thyroid Carcinoma
Abstract
This prospective study aimed to investigate the combination of shear wave elastography (SWE) and BRAFV600E mutation testing for the diagnosis of papillary thyroi...

